Polyclonal Wilms Tumor 1; Anti-Wilms Tumor 1; Wilms tumor 1; Wilms Tumor 1; WAGR; GUD; WT33; AWT1; Wilms Tumor -1; NPHS4; WIT-2; amino-terminal domain of EWS|last three Zinc fingers of the DNA-binding domain of WT1; Wilms tumor protein; WT1

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

IgG

Rabbit

Wilms Tumor 1 antibody was purified by antigen-affinity chromatography

Supplied as a concentrated soloution containing 0.1M Tris, 0.1M Glycine, 10% Glycerol (pH 7.0). 0.01% Thimerosal was added as a preservative.

0.21 mg/ml (lot specific)

Store at 4 degree C for short term storage. Aliquot and store at -20 degree C for long term storage. Avoid repeated freeze/thaw cycles.

Small volumes of anti-WT1 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Affinity purified Rabbit polyclonal Wilms Tumor 1 antibody

DNA & RNA; Purified Polyclonal Antibodies

Immunofluorescence (IF), Immunocytochemistry (ICC), Immunohistochemistry (IHC) Paraffin, Western Blot (WB)

IF:1:100-1:1000
ICC:1:100-1:1000
IHC-P: 1:100-1:1000
WB: 1:500-1:3000

Immunofluorescence analysis of paraformaldehyde-fixed HeLa, using WT1 antibody at 1:200 dilution.

Western blot analysis of 30 ug of whole cell lysate (A: Molt-4; B: Raji) using a 10 % SDS PAGE gel and Wilms Tumor 1 antibody at a dilution of 1:1000

Immunohistochemical staining of paraffin-embedded RT2 xenograft using Wilms Tumor 1 antibody at a dilution of 1:500

56 kDa[Similar Products]

Wilms tumor 1

Wilms tumor protein

Wilms tumor protein

WT1_HUMAN

This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilms tumor. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic, and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple transcript variants have been described. In several variants, there is evidence for the use of a non-AUG (CUG) translation initiation codon upstream of, and in-frame with the first AUG. Authors of PMID:7926762 also provide evidence that WT1 mRNA undergoes RNA editing in human and rat, and that this process is tissue-restricted and developmentally regulated. [provided by RefSeq, Mar 2015]

WT1: a DNA binding protein and apparent transcriptional regulator. Recognizes and binds to the DNA sequence 5'-CGCCCCCGC-3'. Expressed in the kidney and a subset of hematopoietic cells. Defects in WT1 are the cause of Wilms tumor 1 (WT1), an embryonal malignancy of the kidney that affects approximately 1 in 10'000 infants and young children. It occurs both in sporadic and hereditary forms. Four alternatively spliced isoforms have been described.

Protein type: Tumor suppressor; DNA-binding; Nucleolus; Transcription factor; C2H2-type zinc finger protein

Chromosomal Location of Human Ortholog: 11p13

Cellular Component: nucleoplasm; cytoplasm; nucleolus; nuclear speck; nucleus

Molecular Function: protein binding; zinc ion binding; sequence-specific DNA binding; RNA binding; transcription factor activity

Biological Process: tissue development; gonad development; positive regulation of apoptosis; heart development; positive regulation of transcription, DNA-dependent; thorax and anterior abdomen determination; negative regulation of transcription from RNA polymerase II promoter; glomerulus development; germ cell development; negative regulation of cell proliferation; regulation of transcription, DNA-dependent; epithelial cell differentiation; ureteric bud development; male genitalia development; kidney development; vasculogenesis; camera-type eye development; transcription, DNA-dependent; adrenal gland development; RNA splicing; male gonad development; glomerular basement membrane development; sex determination; regulation of transcription from RNA polymerase II promoter; ureteric bud branching; negative regulation of translation; positive regulation of transcription from RNA polymerase II promoter; negative regulation of cell growth; negative regulation of transcription, DNA-dependent; negative regulation of apoptosis

Disease: Wilms Tumor, Aniridia, Genitourinary Anomalies, And Mental Retardation Syndrome; Denys-drash Syndrome; Mesothelioma, Malignant; Nephrotic Syndrome, Type 4; Frasier Syndrome; Aniridia; Wilms Tumor 1; Meacham Syndrome

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.